Lexaria Bioscience warrant delisted from Nasdaq

Lexaria Bioscience Corp. has had its warrant class removed from listing and registration on the Nasdaq Stock Market LLC.

Rhea-AI Filing Summary

Lexaria Bioscience Corp. has had its warrant class removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 notification stating that, under Section 12(b) of the Securities Exchange Act of 1934 and related rules, it has complied with its procedures to strike this warrant from listing and registration. The filing identifies only the company’s warrant as the affected class of securities and is signed on behalf of Nasdaq by an authorized officer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexaria Bioscience Corp. disclose in this Form 25 filing?

The document shows that the Nasdaq Stock Market LLC filed a Form 25 to remove a class of Lexaria Bioscience Corp. securities from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.

Which Lexaria Bioscience (LEXX) security is affected by this Nasdaq action?

The filing identifies warrants of Lexaria Bioscience Corp. as the specific class of securities being removed from listing and registration on the Nasdaq Stock Market LLC.

Who initiated the delisting of Lexaria Bioscience’s warrant from Nasdaq?

The Nasdaq Stock Market LLC initiated the process, certifying on Form 25 that it has reasonable grounds to believe it meets all requirements for filing to remove the Lexaria Bioscience Corp. warrant from listing and registration.

Under which regulations was Lexaria Bioscience’s warrant removed from listing?

The removal is carried out under Section 12(b) of the Securities Exchange Act of 1934 and related rules, including 17 CFR 240.12d2-2, which govern the striking of securities from listing and registration.

Does this Form 25 cover all Lexaria Bioscience (LEXX) securities?

The document specifically describes the affected class of securities as a warrant of Lexaria Bioscience Corp.; it does not describe other classes of the company’s securities.

Who signed the Nasdaq Form 25 for Lexaria Bioscience’s warrant?

The notification is signed on behalf of Nasdaq Stock Market LLC by Tara Petta, identified as an AVP, certifying the exchange’s compliance with Form 25 requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 07:52 AM EST Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39874

Issuer:	Lexaria Bioscience Corp.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	100 - 740 McCurdy Road
	Kelowna/ British Columbia	ILLINOIS	V1X 2P7
Telephone number:					250-765-6424 (203)

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

warrant

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-01-13	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.